If certain performance milestones are achieved in 2008, a further consideration, up to a maximum of $10 million may be payable.
Peter Gray, CEO of Icon, said: “The acquisition of Healthcare Discoveries is an important step for Icon. It gives us a clinical pharmacology platform in the US to complement our existing European Phase I operations.”